Novel Therapeutic Approach to Invasive Group A Streptococcal Disease

侵袭性 A 组链球菌疾病的新治疗方法

基本信息

  • 批准号:
    10452033
  • 负责人:
  • 金额:
    $ 23.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-05 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Microbial-derived Short Chain Fatty Acids (SCFAs) have emerged as important mediators of “Disease Tolerance,” a process that seeks to limit collateral damage to host tissues that accompanies immune responses. SCFAs are the principle end-products of the metabolism of the Gram-positive pathogen Streptococcus pyogenes which can cause several severe invasive diseases that are notoriously difficult to treat due to extensive and rapid tissue destruction that limits perfusion of antibiotics to the site of bacterial multiplication. For the most severe manifestations, in particular necrotizing fasciitis, lesions expand to involve additional tissue at a rapid rate that can approach several cm per hour. This necessitates multiple rounds of aggressive and disfiguring surgical interventions, including debridement, fasciotomy and even amputation of limbs and this lack of therapeutic options results in high mortality. An important gap in our treatment arsenal is the lack of therapies to mitigate tissue damage during severe invasive disease, which would improve the efficacy of antibiotic treatment to promote clearance of the infection. The goal of this study is to explore proof-of-principle that therapeutic manipulation of streptococcal pyruvate metabolism can provide a viable strategy for mitigation of tissue damage to improve treatment outcomes of severe, invasive S. pyogenes disease. This concept builds upon our preliminary data that suggests S. pyogenes employs its several alternative pathways for pyruvate reduction to actively manipulate the host’s “Disease Tolerance” response to promote its ability to infect diverse host niches. Disease tolerance is the process the host employs to balance pathogen growth against the collateral damage to host tissues that accompanies immune responses, known as Growth/Damage Balance. Through identification of host cells and relevant signaling pathways that control disease tolerance, a therapeutic approach that targets microbial metabolic and host cell signaling pathways can reduce damage to tissue to improve the ability of antibiotics to clear infections.
摘要 微生物来源的短链脂肪酸(SCFA)已成为重要的介导剂, “疾病耐受性”是一个试图限制对宿主组织的附带损害的过程, 伴随着免疫反应。SCFA是代谢的主要终产物, 革兰氏阳性病原体化脓性链球菌可引起几种严重侵袭性 由于广泛和快速的组织破坏, 限制了抗生素在细菌增殖部位的灌注。应付最严峻的 表现,特别是坏死性筋膜炎,病变扩大到涉及额外的组织, 速度很快,可以达到每小时几厘米。这需要多轮积极的 和毁容的外科手术,包括清创术,筋膜切开术,甚至截肢, 这种治疗选择的缺乏导致高死亡率。一个重要的差距,在我们的 治疗武器库是缺乏治疗,以减轻组织损伤,在严重的侵入性 疾病,这将提高抗生素治疗的疗效,以促进清除 感染本研究的目的是探讨原则的证明,治疗操作的 链球菌丙酮酸代谢可提供减轻组织损伤的可行策略 以改善严重、侵袭性链球菌的治疗结果。化脓性疾病这个概念建立在 根据我们的初步数据表明S.化脓性链球菌利用其几种替代途径, 丙酮酸减少,以积极操纵宿主的“疾病耐受性”反应, 它能够感染不同的宿主生态位。疾病耐受性是宿主用来 平衡病原体生长和伴随免疫的宿主组织的附带损害 这就是所谓的增长/损害平衡。通过鉴定宿主细胞和相关的 控制疾病耐受性的信号通路,一种针对微生物的治疗方法 代谢和宿主细胞信号传导途径可以减少对组织的损伤,以提高 抗生素来清除感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael G. Caparon其他文献

Volatile profiling distinguishes emStreptococcus pyogenes/em from other respiratory streptococcal species
挥发性分析区分化脓性链球菌和其他呼吸道链球菌物种
  • DOI:
    10.1128/msphere.00194-23
  • 发表时间:
    2023-09-28
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Amalia Z. Berna;Joseph A. Merriman;Leah Mellett;Danealle K. Parchment;Michael G. Caparon;Audrey R. Odom John;Jacqueline M. Achkar
  • 通讯作者:
    Jacqueline M. Achkar
Streptococcus pyogenes protein F promotes invasion of HeLa cells.
化脓性链球菌蛋白 F 促进 HeLa 细胞的侵袭。
  • DOI:
    10.1099/00221287-144-11-3079
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    1.5
  • 作者:
    Nobuhiko Okada;lchiro Tatsuno;Emanuel Hanski;Michael G. Caparon;C. Sasakawa
  • 通讯作者:
    C. Sasakawa
Reprogramming aerobic metabolism mitigates Streptococcus pyogenes tissue damage in a mouse necrotizing skin infection model
在小鼠坏死性皮肤感染模型中,重新编程有氧代谢可减轻化脓性链球菌组织损伤。
  • DOI:
    10.1038/s41467-025-57348-x
  • 发表时间:
    2025-03-15
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Wei Xu;Tara R. Bradstreet;Zongsen Zou;Suzanne Hickerson;Yuan Zhou;Hongwu He;Brian T. Edelson;Michael G. Caparon
  • 通讯作者:
    Michael G. Caparon
MP23-19 FIBRINOGEN DEPOSITS ON URINARY CATHETERS IN A TIME-DEPENDENT MATTER AND CO-LOCALIZES WITH <em>E. FAECALIS</em> IN PATIENTS WITH POSITIVE <em>E. FAECALIS</em> URINE CULTURES
  • DOI:
    10.1016/j.juro.2017.02.747
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tyler M. Bauman;Aaron M. Potretzke;Ana L. Flores-Mireles;Jennifer N. Walker;Alyssa M. Park;Henry L. Schreiber;Jerome S. Pinkner;Michael G. Caparon;Scott J. Hultgren;Alana Desai
  • 通讯作者:
    Alana Desai

Michael G. Caparon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael G. Caparon', 18)}}的其他基金

Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
侵袭性 A 组链球菌疾病的新治疗方法
  • 批准号:
    10546470
  • 财政年份:
    2022
  • 资助金额:
    $ 23.63万
  • 项目类别:
Characterization of assembly factors for type IV secretion systems
IV 型分泌系统组装因子的表征
  • 批准号:
    10435561
  • 财政年份:
    2021
  • 资助金额:
    $ 23.63万
  • 项目类别:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
GmPcides:解除多种革兰氏阳性病原体抗生素耐药性的化合物
  • 批准号:
    10577811
  • 财政年份:
    2021
  • 资助金额:
    $ 23.63万
  • 项目类别:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
GmPcides:解除多种革兰氏阳性病原体抗生素耐药性的化合物
  • 批准号:
    10162829
  • 财政年份:
    2021
  • 资助金额:
    $ 23.63万
  • 项目类别:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
GmPcides:解除多种革兰氏阳性病原体抗生素耐药性的化合物
  • 批准号:
    10352471
  • 财政年份:
    2021
  • 资助金额:
    $ 23.63万
  • 项目类别:
Structure-function analysis of type IVB secretion systems
IVB型分泌系统的结构-功能分析
  • 批准号:
    10624264
  • 财政年份:
    2019
  • 资助金额:
    $ 23.63万
  • 项目类别:
EBPA-FIBROGEN INTERACTION IN ENTEROCOCCUS FAECALIS CAUTI
粪肠球菌中 EBPA-纤维原的相互作用
  • 批准号:
    9304949
  • 财政年份:
    2014
  • 资助金额:
    $ 23.63万
  • 项目类别:
EBPA-FIBROGEN INTERACTION IN ENTEROCOCCUS FAECALIS CAUTI
粪肠球菌中 EBPA-纤维原的相互作用
  • 批准号:
    8759401
  • 财政年份:
    2014
  • 资助金额:
    $ 23.63万
  • 项目类别:
EBPA-FIBROGEN INTERACTION IN ENTEROCOCCUS FAECALIS CAUTI
粪肠球菌中 EBPA-纤维原的相互作用
  • 批准号:
    8901925
  • 财政年份:
    2014
  • 资助金额:
    $ 23.63万
  • 项目类别:
CATABOLITE REPRESSION CONTROLS VIRULENCE IN STREPTOCOCCUS PYOGENES
分解代谢物抑制控制化脓性链球菌的毒力
  • 批准号:
    9174072
  • 财政年份:
    2007
  • 资助金额:
    $ 23.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了